- Ticker
- ACST
- Price
- 0.89
- Stock movement down
- -0.00 (-0.37%)
- Company name
- Acasti Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 39.49M
- Ent value
- 29.50M
- Price/Sales
- 308.51
- Price/Book
- 0.36
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -76.37%
- 3 year return
- -60.34%
- 5 year return
- -39.05%
- 10 year return
- -
Last updated: 2022-08-25
DIVIDENDS
ACST does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 308.51 |
| Price to Book | 0.36 |
| EV to Sales | 230.47 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 44.44M |
| EPS (TTM) | -0.66 |
| FCF per share (TTM) | -1.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 128.00K |
| Gross profit (TTM) | 75.00K |
| Operating income (TTM) | -15.59M |
| Net income (TTM) | -9.82M |
| EPS (TTM) | -0.66 |
| EPS (1y forward) | -0.55 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 58.59% |
| Operating margin (TTM) | -12178.91% |
| Profit margin (TTM) | -7671.09% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.34M |
| Net receivables | 548.00K |
| Total current assets | 45.53M |
| Goodwill | 12.96M |
| Intangible assets | 69.81M |
| Property, plant and equipment | 0.00 |
| Total assets | 128.62M |
| Accounts payable | 1.68M |
| Short/Current long term debt | 295.00K |
| Total current liabilities | 3.26M |
| Total liabilities | 20.35M |
| Shareholder's equity | 108.27M |
| Net tangible assets | 25.50M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -17.23M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -17.23M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -9.07% |
| Return on Assets | -7.63% |
| Return on Invested Capital | -9.06% |
| Cash Return on Invested Capital | -15.90% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.89 |
| Daily high | 0.89 |
| Daily low | 0.88 |
| Daily Volume | 60K |
| All-time high | 325.60 |
| 1y analyst estimate | 5.04 |
| Beta | 1.43 |
| EPS (TTM) | -0.66 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 Nov 2022 |
Downside potential
Loading...
Downside potential data
| ACST | S&P500 | |
| Current price drop from All-time high | -99.73% | -12.18% |
| Highest price drop | -99.75% | -56.47% |
| Date of highest drop | 1 Aug 2022 | 9 Mar 2009 |
| Avg drop from high | -84.28% | -11.38% |
| Avg time to new high | 72 days | 12 days |
| Max time to new high | 2272 days | 1805 days |
COMPANY DETAILS
Marketcap
39.49M
Marketcap category
Small-cap
Description
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Janelle D'Alvise
Country
USA
City
Laval
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies a...
September 21, 2022
LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability an...
September 14, 2022
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) brid...
September 13, 2022
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability an...
September 12, 2022
Q1 2023 Acasti Pharma Inc Earnings Call
August 11, 2022
Company to Host Conference Call Today at 1:00pm ETLAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialt...
August 11, 2022
Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today a...
August 2, 2022
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridg...
July 27, 2022
Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and nov...
July 7, 2022
LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and...
June 22, 2022
Next page